- Global Pharma News & Resources

Plasmid DNA Manufacturing Market Size Is Estimated to Grow at a CAGR of 23.7% By 2026 | Future Trends, Insights, Share, Dynamics and Global DNA Manufacturing Industry Overview

Global Plasmid DNA Manufacturing Market

Plasmid DNA (pDNA) plays a crucial role in modern healthcare, as it is used directly as a therapeutic agent in gene therapy or generation of vaccine antigens. Furthermore, pDNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including RNA, in-vitro protein production, and cell therapies.

The global plasmid DNA manufacturing market was pegged at US$ 65.1 million in 2017, and is foreseen to exhibit a magnificent CAGR of 23.7% over the forecast period (2018-2026).

To get a holistic SAMPLE of the report including the table of contents, please click

Figure 1. Global Plasmid DNA Manufacturing Market Value (US$ Mn), by Region, 2017

Source: Coherent Market Insights Analysis (2019)

Increasing number of patients opting for gene therapies is expected to propel the global market expansion

Increasing number of patients opting for gene therapy is a major factor driving growth of the plasmid DNA manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases. For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection leads to improved vision of individuals suffering from Leber’s Congenital Amaurosis.

Several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on the potential of gene therapy. Increasing investments in drug development and commercialization of these therapies in order to meet significant medical needs are factors driving the market growth. These genetic markers are associated with complex diseases, therefore it is important to study about the genetic information and its clinical application in designing clinical trials and gene therapy product manufacturing.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

As per the data published by the Journal of Gene Medicine in March 2018, an estimated 2,600 gene therapy clinical trials has been ongoing, were already completed, or had been approved in about 36 countries. Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, Severe Combined Immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Figure 2. Global Plasmid DNA Manufacturing Market Share (%), by Application, 2018 and 2026

Source: Coherent Market Insights Analysis (2019)

Collaborations by market players is expected to bolster the market growth in Europe

Europe is anticipated to witness significant growth in the global plasmid DNA manufacturing market, thanks to the increasing adoption of effective growth strategies, such as collaborations, by the key market players. For instance, in May 2018, PlasmidFactory GmbH & Co. KG collaborated with Sirion-Biotech GmbH, Vibalogics GmbH, and PROGEN for adeno-associated virus (AAV) vector manufacturing. This collaboration was done to accelerate timeline and to create easy workflow from plasmid manufacturing to GMP production, and analytics of recombinant AAV to fulfil the customers’ requirement of AAV vector.

View Press Release For More Information @

Leading Market Players

The most prominent players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing.

Detailed Segmentation:

  • Global Plasmid DNA Manufacturing Market, By Product Type:
    • High Quality (HQ) Plasmid DNA
    • GMP Grade Plasmid DNA
    • Non-GMP Grade Plasmid DNA
  • Global Plasmid DNA Manufacturing Market, By Application:
    • DNA Vaccines
    • Gene Therapy
    • Immunotherapy
    • Others
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 21-Dec-2020